The End of Heart Disease in a SINGLE Dose?

*JOIN THE PHYSIONIC INSIDERS [PREMIUM CONTENT]*Join the Physionic Insiders: https://bit.ly/PhysionicInsiders2 *HEALTH AUTONOMY [COURSE]*Learn to Analyze & Apply Studies for Yourself: https://bit.ly/healthautonomy*JOIN THE COMMUNITY*Join my Community [It’s Free!]: https://bit.ly/PhysionicCommunity2*EMAIL LIST*1-2 Weekly Email of Value [It’s Free!]: http://bit.ly/2AXIzK6*HIRE ME FOR CONSULTING:* Consulting: https://bit.ly/3dmUl2H Created with Biorender0:00 - Introduction0:28 - Cholesterol and Heart Disease5:00 - Professor X will see you now…7:58 - The TerrifyingReferences[1] Vafai SB, Täubel J, Ashdown T, et al. In vivo base editing of PCSK9 with VERVE-102 for hypercholesterolemia. N Engl J Med. Published online May 25, 2026. doi:10.1056/NEJMoa2601283.[2] Rohde E, Lee RG, Mazzola AM, et al. Nonclinical data demonstrate potent and precise inactivation of liver PCSK9 in vivo with clinical stage GalNAc base editing medicine, VERVE-102. Presented at: 93rd European Atherosclerosis Society Congress; May 4-7, 2025; Glasgow, UK.[3] Ibanez B, Fernández-Ortiz A, Fernández-Friera L, et al. Progression of early subclinical atherosclerosis (PESA) study: JACC focus seminar 7/8. J Am Coll Cardiol. 2021;78(2):156-179. doi:10.1016/j.jacc.2021.05.011.[4] Ference BA, Yoo W, Alesh I, et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol. 2012;60(25):2631-2639. doi:10.1016/j.jacc.2012.09.017.Please use the following link to submit your critique: https://bit.ly/PhysionicCritiqueDisclaimer: None of the information provided by this brand is a replacement for your physician's advice. This brand is information for the sake of knowledge and the options of choice it provides, not in any way a personalized prescription. Please consult your physician before making any health related changes.